Suggested remit: To appraise the clinical and cost effectiveness of datopotamab within its marketing authorisation for treating advanced non-small-cell lung cancer after platinum-based chemotherapy with or without immunotherapy or a targeted anti-cancer treatment.
 
Status In progress
Technology type Medicine
Decision Selected
Reason for decision Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources
Process STA Standard
ID number 6241

Provisional Schedule

Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: 6241 09 July 2024 - 06 August 2024

Email enquiries

Timeline

Key events during the development of the guidance:

Date Update
25 July 2024 Please note that following on from a request received from the company, the timelines for this appraisal have been revised and the appraisal is now anticipated to begin late October 2024. The deadline for submissions is expected in approximately early January 2025. These timings are based on a request from the company to reschedule the initial date set by NICE, in order to align with regulatory timelines. Although timelines have changed this does not affect the scoping consultation, the deadline for consultation comments will remain as is.
09 July 2024 In progress. Scoping commencing
06 February 2023 Awaiting development. Status change linked to Topic Selection Decision being set to Selected

For further information on our processes and methods, please see our CHTE processes and methods manual